| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
45,073 |
40,937 |
$7.47M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
38,228 |
21,069 |
$241K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
25,821 |
14,590 |
$210K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,019 |
2,206 |
$49K |
| G9920 |
Screening performed and negative |
2,779 |
1,605 |
$39K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,609 |
1,994 |
$39K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,946 |
1,070 |
$29K |
| 92551 |
|
9,401 |
5,156 |
$28K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,326 |
1,452 |
$27K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
601 |
349 |
$18K |
| 90686 |
|
2,905 |
1,768 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,522 |
983 |
$14K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,958 |
1,147 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
6,332 |
3,562 |
$11K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
3,193 |
2,695 |
$9K |
| 90670 |
|
1,405 |
850 |
$7K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
435 |
268 |
$6K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
5,962 |
5,074 |
$5K |
| G9919 |
Screening performed and positive and provision of recommendations |
275 |
157 |
$4K |
| 90651 |
|
565 |
314 |
$4K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
192 |
122 |
$4K |
| 99173 |
|
6,623 |
5,036 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
113 |
63 |
$3K |
| 90648 |
|
738 |
430 |
$3K |
| 90698 |
|
703 |
454 |
$3K |
| 96127 |
|
1,211 |
712 |
$3K |
| 90734 |
|
370 |
200 |
$3K |
| 90633 |
|
643 |
365 |
$3K |
| 81003 |
|
2,263 |
1,245 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
170 |
103 |
$2K |
| 90723 |
|
466 |
278 |
$2K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
216 |
193 |
$2K |
| 99215 |
Prolong outpt/office vis |
51 |
27 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
272 |
74 |
$1K |
| 90744 |
|
346 |
232 |
$1K |
| 90677 |
|
144 |
84 |
$962.12 |
| 90680 |
|
160 |
99 |
$713.63 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
42 |
26 |
$682.20 |
| 90656 |
|
102 |
79 |
$661.24 |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
98 |
91 |
$623.23 |
| 99188 |
|
67 |
43 |
$468.00 |
| 90715 |
|
90 |
49 |
$462.77 |
| 99381 |
|
15 |
12 |
$373.16 |
| 93000 |
|
49 |
28 |
$348.49 |
| 90696 |
|
94 |
53 |
$344.46 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
77 |
51 |
$338.92 |
| 90710 |
|
72 |
42 |
$289.80 |
| 90707 |
|
67 |
38 |
$282.40 |
| 90681 |
|
107 |
78 |
$244.94 |
| 81025 |
|
158 |
89 |
$235.93 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
224 |
145 |
$195.45 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
26 |
16 |
$138.08 |
| 90716 |
|
22 |
13 |
$81.98 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,224 |
791 |
$4.93 |
| 1036F |
|
1,623 |
1,502 |
$0.00 |
| 3074F |
|
2,239 |
2,106 |
$0.00 |
| 3075F |
|
232 |
223 |
$0.00 |
| 3008F |
|
1,879 |
1,773 |
$0.00 |
| 3079F |
|
304 |
297 |
$0.00 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
29 |
28 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
16 |
15 |
$0.00 |
| 3080F |
|
18 |
14 |
$0.00 |
| 3078F |
|
2,249 |
2,121 |
$0.00 |
| 3077F |
|
116 |
109 |
$0.00 |
| 3725F |
|
128 |
128 |
$0.00 |
| 1159F |
|
124 |
119 |
$0.00 |
| 1160F |
|
124 |
119 |
$0.00 |